Stock Ratings / Health Care / DXCM / earnings

WST (81) RMD (86) MDLN (44) BDX (67) ⌘ Pro Terminal →

DexCom Inc. (DXCM) Next Earnings Date & Expected ±6.7% Move

$79.93 +1.67% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

DexCom Inc. (DXCM) earns a Roarable Rating of B+ (Buy) with 76/100 RQD Confidence. High-quality cash engine (60% profit margin, 22% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B+ • BUY Cap $30.16B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERBUY • B+

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk B+

Each axis scored 0–20

12M PRICE TARGET CONE+8.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DXCM)Realized 20D OHLCV Swing Band: ±6.7%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±6.7% Swing Band

±$5.36 Expected Swing

MODEL EARNINGS SETUP GAUGE

DXCM Quantitative Pre-Earnings Setup: 76/100

Trailing EPS: $2.22 • YoY Revenue Growth: 15.6%

Model Bullish Setup (76/100)Model Risk Weight (24/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$4.66B	$836.3M	$1.08B	60.1%
FY 2024	2024-12-31	$4.03B	$576.2M	$630.7M	60.5%
FY 2023	2023-12-31	$3.62B	$541.5M	$585.5M	60.1%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating DXCM & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on DXCM
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

DXCM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +33.13%🛡️ HOLDING TREND SUPPORT

2026-11-01O $78.62H $79.93L $78.62C $79.93VOL 5.92M

RES: $87.79SUP: $77.08SMA50: $85.57SMA200: $74.61

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DXCM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DXCM Butterfly Map → + Track DXCM →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

27.8%/yr Implied 5Y Growth

vs. +15.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on DXCM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

LLY → DXCM Analyst Hypothesis

Real-world payer claims data show clinicians co-prescribe Dexcom G7 and OTC Stelo continuous glucose monitors (CGMs) alongside GLP-1 initiation for metabolic feedback, offsetting delayed progression to basal insulin.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for DXCM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DXCM)

Health Care Rank #27 of 188 ⚔️ WST vs DXCM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DXCM vs. WST, RMD, MDLN, BDX)

Industry: Medical/Dental Instruments (21 Tracked Issuers)

Across 188 tracked Health Care securities in the Roarable RQD universe, DexCom Inc. (DXCM) ranks #27 by composite RQD confidence (76/100, grade B+) and #57 by equity capitalization ($30.16B). Within this direct 5-issuer industry benchmark cohort, RMD leads on earnings valuation at 25.4x trailing P/E, while RMD leads on capital efficiency and profitability with 22.9% ROIC and 59.4% gross margin. RMD currently holds the highest overall quantitative score in the immediate peer group at 86/100 (A) compared with DXCM at 76/100 (B+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
DXCM ACTIVE DexCom Inc.	B+	76/100	36.1x	60.1%	21.6%	+1.67%	$30.16B	Benchmark Subject
WST West Pharmaceutical Services Inc.	A-	81/100	59.4x	35.9%	17.9%	+3.23%	$29.32B	/wst-vs-dxcm →
RMD ResMed Inc.	A	86/100	25.4x	59.4%	22.9%	+1.06%	$35.56B	/rmd-vs-dxcm →
MDLN Medline Inc.	D	44/100	—	—	8.2%	-1.14%	$42.07B	/mdln-vs-dxcm →
BDX Becton Dickinson and Company	C+	67/100	32.2x	45.4%	4.9%	+1.63%	$54.03B	/bdx-vs-dxcm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001093557

In its most recent audited fiscal period (FY2025, filed 2025-12-31), DexCom Inc. (DXCM) reported GAAP revenue of $4.66B (+15.6% vs. FY2024 revenue of $4.03B , and +28.7% cumulative change since FY2023) , GAAP net income of $836.3M, operating cash flow of $1.44B, and free cash flow of $1.08B (+70.8% YoY). On the balance sheet, DXCM closed FY2025 with $6.34B in total assets against $1.62B in total debt (Altman Z-Score: 7.14, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$4.66B	$836.3M	$1.44B	$1.08B	$6.34B	$1.62B
FY2024 (FY)	2024-12-31	$4.03B	$576.2M	$989.5M	$630.7M	$6.48B	$1.97B
FY2023 (FY)	2023-12-31	$3.62B	$541.5M	$748.5M	$585.5M	$16.59B	$3.88B

3. DXCM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DXCM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, DexCom Inc. (NASDAQ: DXCM) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 76/100 at a spot price of $79.93 (+1.67% 1D, market cap $30.16B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 16/20. Across 188 tracked Health Care issuers, DXCM ranks #27 in composite RQD confidence.

How does DXCM compare to WST and RMD in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), DXCM carries a Roarable B+ (76/100 RQD), trailing P/E of 36.1x, gross margin of 60.1%, and ROIC of 21.6%. By comparison, WST (West Pharmaceutical Services Inc.) holds a A- grade (81/100 RQD, P/E 59.4x, ROIC 17.9%, cap $29.32B) and RMD (ResMed Inc.) posts a A grade (86/100 RQD, P/E 25.4x, ROIC 22.9%, cap $35.56B). Among the 5-stock peer group, RMD leads on earnings multiple (25.4x) while RMD leads on capital efficiency (22.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for DXCM?

Per DXCM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001093557), DexCom Inc. generated $4.66B in revenue (+15.6% YoY), $836.3M in net income, and $1.08B in free cash flow against $6.34B in total assets and $1.62B in total debt. Key quantitative strengths: Strong cash generator (60% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is DXCM trading relative to its 50-day, 200-day, and 52-week technical levels?

DXCM last traded at $79.93 (+1.67% on volume of 5,923,929 shares), positioning the stock -6.59% below its 50-day simple moving average ($85.57) and +7.13% above its 200-day simple moving average ($74.61). Across its 52-week range of $54.11 to $92.59, DXCM sits at the 67.1% percentile with a 14-day RSI of 41.8 (NEUTRAL RANGE) and an implied next-earnings move of ±6.7% ($74.57 to $85.29).

DXCM Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is DXCM's next earnings date?

Based on SEC filing cadence, DexCom Inc. (DXCM)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is DXCM stock expected to move on earnings?

Volatility modeling currently projects a ±6.7% event move for DXCM, spanning a range between $74.57 and $85.29.

Direct Sub-Reports: DXCM RQD Cockpit DXCM 12M Forecast DXCM Earnings & Move DXCM Dividends & DRIP DXCM Insiders & 13F DXCM Whale Options DXCM Profit Sankey DXCM News & Why